PHVS
Closed
Pharvaris Bv
17.25
-0.35 (-1.99%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 17.6
Day's Range: 16.72 - 17.85
Send
sign up or login to leave a comment!
When Written:
8.05
Pharvaris BV is a clinical-stage biopharmaceutical company that is focused on developing and commercializing novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-mediated diseases. The company was founded in 2016 and is headquartered in Leiden, the Netherlands. Pharvaris' lead product candidate, PHA121, is a potent, specific, and orally bioavailable bradykinin-B2-receptor antagonist. The company is also developing other product candidates that target the bradykinin pathway for the treatment of various diseases. In 2021, Pharvaris announced positive results from a Phase 2 clinical trial of PHA121 for the treatment of HAE.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








